{"name": "TetraLogic Pharmaceuticals",
 "permalink": "tetralogic-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/tetralogic-pharmaceuticals",
 "homepage_url": "http://www.tetralogicpharma.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@tetralogicpharma.com",
 "phone_number": "610.889.9900",
 "description": "",
 "created_at": "Wed Aug 11 01:26:22 UTC 2010",
 "updated_at": "Tue May 24 11:55:20 UTC 2011",
 "overview": "\u003Cp\u003ETetraLogic Pharmaceuticals is a privately held biopharmaceutical company that discovers and develops small molecule drugs that modulate programmed cell death pathways to treat debilitating diseases and conditions. The company\u00e2\u20ac\u2122s Smac Mimetics neutralize critical blocks in the apoptosis pathway to selectively destroy cancer cells.  Its Necrostatin drugs block critical steps in the process leading to necrosis, enabling cell survival in a wide range of diseases and injuries where necrosis is a critical component of pathology.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       43],
      "assets/images/resized/0009/8561/98561v1-max-150x150.png"],
     [[250,
       72],
      "assets/images/resized/0009/8561/98561v1-max-250x250.png"],
     [[270,
       78],
      "assets/images/resized/0009/8561/98561v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "Founder, President, CEO",
    "person":
     {"first_name": "John",
      "last_name": "M. Gill",
      "permalink": "john-m-gill",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$66M",
 "funding_rounds":
  [{"round_code": "c",
    "source_url": "http://www.fiercebiotech.com/story/tetralogic-nabs-32m-round-lead-cancer-therapy/2010-08-10?utm_medium=rss\u0026utm_source=rss",
    "source_description": "TetraLogic nabs $32M round for lead cancer therapy  Read more: TetraLogic nabs $32M round for lead cancer therapy",
    "raised_amount": 32000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 8,
    "funded_day": 10,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Clarus Ventures",
         "permalink": "clarus-ventures",
         "image":
          {"available_sizes":
            [[[150,
               82],
              "assets/images/resized/0005/0042/50042v2-max-150x150.png"],
             [[250,
               137],
              "assets/images/resized/0005/0042/50042v2-max-250x250.png"],
             [[308,
               169],
              "assets/images/resized/0005/0042/50042v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Hatteras Venture Partners",
         "permalink": "hatteras-venture-partners",
         "image":
          {"available_sizes":
            [[[150,
               39],
              "assets/images/resized/0004/6917/46917v2-max-150x150.png"],
             [[250,
               65],
              "assets/images/resized/0004/6917/46917v2-max-250x250.png"],
             [[393,
               103],
              "assets/images/resized/0004/6917/46917v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Amgen Ventures",
         "permalink": "amgen-ventures",
         "image":
          {"available_sizes":
            [[[150,
               28],
              "assets/images/resized/0023/2414/232414v2-max-150x150.jpg"],
             [[250,
               47],
              "assets/images/resized/0023/2414/232414v2-max-250x250.jpg"],
             [[450,
               84],
              "assets/images/resized/0023/2414/232414v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "HealthCare Ventures",
         "permalink": "healthcare-ventures",
         "image":
          {"available_sizes":
            [[[150,
               20],
              "assets/images/resized/0004/9268/49268v1-max-150x150.jpg"],
             [[250,
               34],
              "assets/images/resized/0004/9268/49268v1-max-250x250.jpg"],
             [[290,
               40],
              "assets/images/resized/0004/9268/49268v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Latterell Venture Partners",
         "permalink": "latterell-venture-partners",
         "image":
          {"available_sizes":
            [[[150,
               21],
              "assets/images/resized/0005/5132/55132v2-max-150x150.png"],
             [[250,
               36],
              "assets/images/resized/0005/5132/55132v2-max-250x250.png"],
             [[287,
               42],
              "assets/images/resized/0005/5132/55132v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Novitas Capital",
         "permalink": "novitas-capital",
         "image":
          {"available_sizes":
            [[[150,
               19],
              "assets/images/resized/0000/3478/3478v2-max-150x150.png"],
             [[200,
               26],
              "assets/images/resized/0000/3478/3478v2-max-250x250.png"],
             [[200,
               26],
              "assets/images/resized/0000/3478/3478v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Quaker BioVentures",
         "permalink": "quaker-bioventures",
         "image":
          {"available_sizes":
            [[[144,
               96],
              "assets/images/resized/0004/9249/49249v2-max-150x150.jpg"],
             [[144,
               96],
              "assets/images/resized/0004/9249/49249v2-max-250x250.jpg"],
             [[144,
               96],
              "assets/images/resized/0004/9249/49249v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "The Vertical Group",
         "permalink": "the-vertical-group",
         "image":
          {"available_sizes":
            [[[150,
               95],
              "assets/images/resized/0005/5098/55098v1-max-150x150.png"],
             [[150,
               95],
              "assets/images/resized/0005/5098/55098v1-max-250x250.png"],
             [[150,
               95],
              "assets/images/resized/0005/5098/55098v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "c",
    "source_url": "https://www.fis.dowjones.com/article.aspx?ProductIDFromApplication=32\u0026aid=DJFVW00020100928e69s00001\u0026r=Rss\u0026s=DJFVW",
    "source_description": "TetraLogic Pharma Boosts Series C To $37M With Pfizer Ventures Capital  ",
    "raised_amount": 5000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2010,
    "funded_month": 9,
    "funded_day": 27,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Pfizer Venture Investments",
         "permalink": "pfizer-venture-investments",
         "image":
          {"available_sizes":
            [[[150,
               97],
              "assets/images/resized/0025/2881/252881v1-max-150x150.png"],
             [[200,
               130],
              "assets/images/resized/0025/2881/252881v1-max-250x250.png"],
             [[200,
               130],
              "assets/images/resized/0025/2881/252881v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "c",
    "source_url": "https://www.fis.dowjones.com/article.aspx?ProductIDFromApplication=32\u0026aid=DJFVW00020110105e716001jl\u0026r=Rss\u0026s=DJFVW",
    "source_description": " TetraLogic Pulls Down $23M Series C Tranche For Cancer Trials",
    "raised_amount": 23000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 1,
    "funded_day": 4,
    "investments":
     []},
   {"round_code": "c",
    "source_url": "http://www.streetinsider.com/Press+Releases/TetraLogic+Closes+$6+Million+Series+C-1+Investment+with+Nextech+Invest+Ltd./6532663.html",
    "source_description": "TetraLogic Closes $6 Million Series C-1 Investment with Nextech Invest Ltd",
    "raised_amount": 6000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2011,
    "funded_month": 5,
    "funded_day": 24,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Nextech Venture",
         "permalink": "nextech-venture",
         "image": null},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "343 Phoenixville Pike",
    "address2": "",
    "zip_code": "19355",
    "city": "Malvern",
    "state_code": "PA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}